Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers
A phase 2/3 trial of FOLFOX in gallbladder cancer and other biliary tract cancers, run by UNICANCER, not yet recruiting.
Overview
Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers is a phase 2/3, randomised interventional study registered as NCT07437287 by UNICANCER, with a registry enrolment figure of 160 participants, started 2026-07 and due to reach its primary completion in 2030-04. Interventions recorded: mFOLFOX regimen, Mitazalimab. Conditions listed: Biliary Tract Cancer (BTC). Gallbladder cancer is named in the registry entry: "2. Histologically-proven intrahepatic cholangiocarcinoma, extrahepatic (perihilar/distal) cholangiocarcinoma, or gallbladder carcinoma (ampullary carcinoma excluded)". Sites: France. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAdjuvant Chemotherapy for BTC Based on 3D-PTA
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialAdoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialmFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
Shares Ampullary cancer (ampulla of Vater), FOLFOX (5-FU, leucovorin, oxaliplatin), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma and the tag gallbladder-deep-dive.
- TrialA Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialQL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialPrecision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialPD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.